HCV Infection Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Phase I Study to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple ascending doses of SH229 in patients with chronic hepatitis C Virus infection.
A total of 30 evaluable patients will be enrolled in this study. The planned dose levels are 400, 600, and 800 mg. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03674125 -
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
|
Phase 1 | |
Completed |
NCT00978497 -
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
|
Phase 2 | |
Completed |
NCT00170131 -
MMF Influence on HCV Viral Evolution After Liver Transplantation
|
Phase 4 | |
Completed |
NCT04008927 -
A Community-based Intervention Among Active Drug Users in Montpellier
|
N/A | |
Active, not recruiting |
NCT04044586 -
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
|
||
Completed |
NCT01958281 -
Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency
|
Phase 2 | |
Completed |
NCT02533427 -
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
|
Phase 1 | |
Completed |
NCT02783976 -
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
|
||
Withdrawn |
NCT04309734 -
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
|
Phase 1/Phase 2 | |
Completed |
NCT01965535 -
Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection
|
Phase 2 | |
Completed |
NCT00743795 -
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
|
Phase 2 | |
Completed |
NCT00768690 -
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333
|
Phase 1 | |
Withdrawn |
NCT04235049 -
Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)
|
Phase 4 | |
Terminated |
NCT00401947 -
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
|
Phase 2 | |
Completed |
NCT00959699 -
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
|
Phase 2 | |
Completed |
NCT00623649 -
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
|
Phase 1 | |
Completed |
NCT00221624 -
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
|
Phase 3 | |
Completed |
NCT04134767 -
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)
|
N/A | |
Completed |
NCT02402452 -
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
|
Phase 1 | |
Completed |
NCT00909311 -
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
|
Phase 1 |